Compounded Tirzepatide Dosage Chart & Titration Schedule
Compounded tirzepatide prescriptions may use different concentrations and delivery formats. Use this guide to check dose-to-volume calculations, understand U-100 syringe markings, and distinguish brand dosing schedules from your pharmacy-specific instructions. Start with two numbers on your prescription: the dose in milligrams and the concentration in milligrams per milliliter.
Understanding Tirzepatide: Mechanism and Advantages
Tirzepatide is a dual GLP-1/GIP receptor agonist. The approved brands use this active ingredient for different labeled indications, and the current US Mounjaro labeling and Zepbound prescribing information control their product-specific dosing and presentations.
In the 72-week open-label randomized SURMOUNT-5 trial, 751 adults with obesity without type 2 diabetes received maximum tolerated tirzepatide doses of 10 or 15mg or semaglutide doses of 1.7 or 2.4mg. Mean weight changes were -20.2% and -13.7%, respectively. This supports a benefit for the studied treatments; it does not establish equivalent results for a compounded preparation.
Gastrointestinal effects can occur during dose escalation. A prescriber may adjust a branded schedule based on response and tolerability, and a compounded prescription still requires its own labeled concentration and instructions. Do not treat the arithmetic table below as a compulsory 15mg ladder or as permission to advance every 2-3 weeks.
A compounded preparation can be made for an individual medical need, but the FDA distinguishes compounded products from approved generics and therapeutic equivalents. Do not infer finished-product equivalence, guaranteed potency, or identical delivery from the active-ingredient name alone. Follow the dispensing pharmacy label, prescriber instructions, and applicable storage and beyond-use information.
Brand Tirzepatide Titration and Compounded Prescriptions
The adult Zepbound schedule starts at 2.5mg weekly for 4 weeks, then increases to 5mg. Later increases are in 2.5mg steps after at least 4 weeks at the current dose, with maintenance selected for response and tolerability. Weight-management maintenance doses are 5, 10, or 15mg weekly; obstructive sleep apnea maintenance doses are 10 or 15mg. The 2.5mg dose is for initiation, not maintenance.
The current Mounjaro label starts at 2.5mg weekly and permits 2.5mg increases after at least 4 weeks if additional glycemic control is needed. Both brands have an adult maximum of 15mg weekly. These adult references should not be applied to pediatric dosing.
That brand schedule is a reference for the approved brand presentation, not approval of a compounded formulation. A compounded prescription may use a different labeled concentration, volume, formulation, or device. Use the pharmacy label and prescriber plan rather than an automatic ladder, an accelerated 2-3 week interval, or an assumption that every patient should reach 15mg.
Missed-dose timing also belongs to the named product. Current Lilly labeling uses a 96-hour window for a missed dose and keeps doses at least 72 hours apart. If your compounded label differs or you have missed multiple doses, ask the prescriber or pharmacy for a plan rather than improvising a restart.
Tirzepatide Dosage Chart: Complete Titration with Volume Conversions
Find the prescribed dose, then use the column matching your pharmacy-labeled concentration. These three concentrations are examples, not a list of what every pharmacy supplies. The rows are dose conversions, not weeks of treatment or instructions to increase a dose.
| Adult brand-label reference | Dose (mg) | Volume @ 5mg/mL | Volume @ 10mg/mL | Volume @ 20mg/mL | Reference frequency |
|---|---|---|---|---|---|
| Starting dose | 2.5 | 0.5 mL | 0.25 mL | 0.125 mL | Once weekly |
| Zepbound weight maintenance option | 5.0 | 1.0 mL | 0.5 mL | 0.25 mL | Once weekly |
| Intermediate escalation dose | 7.5 | 1.5 mL | 0.75 mL | 0.375 mL | Once weekly |
| Zepbound maintenance option | 10.0 | 2.0 mL | 1.0 mL | 0.5 mL | Once weekly |
| Intermediate escalation dose | 12.5 | 2.5 mL | 1.25 mL | 0.625 mL | Once weekly |
| Adult maximum; Zepbound maintenance option | 15.0 | 3.0 mL | 1.5 mL | 0.75 mL | Once weekly |
These volumes are dose divided by concentration. Some exceed a stated 1mL capacity; whether the remaining volumes can be measured depends on the device specified by your pharmacy. A correct calculation still needs a device that can measure and hold the prescribed volume. Ask the pharmacy to resolve a mismatch rather than rounding or dividing the injection yourself.
Understanding Vial Concentrations and Practical Selection
The 5mg/mL, 10mg/mL, and 20mg/mL columns are illustrative concentrations for the calculation. They are not a claim that every pharmacy stocks those concentrations or that one concentration is right for every prescription. Use the exact concentration on the dispensing label.
At 5mg/mL, the table spans 0.5-3.0mL; at 10mg/mL, 0.25-1.5mL; and at 20mg/mL, 0.125-0.75mL. Those are volume ranges, not a claim that one syringe or vial can hold or accurately deliver the entire range. Under the stated U-100 arithmetic convention, a 1.5mL volume is 150 units and a 3mL volume is 300 units; the pharmacy must match the sterile measuring device and labeled dose.
For the arithmetic below, the stated U-100 convention is 100 units per mL. One unit is treated as 0.01mL, which equals 0.05mg at 5mg/mL, 0.1mg at 10mg/mL, or 0.2mg at 20mg/mL. This convention does not establish that a particular device is U-100 or guarantee delivery accuracy. For example, 0.125mL is 12.5 U-100 units, while 0.375mL is 37.5 units and 0.625mL is 62.5 units. A whole-unit scale cannot display those half-unit values exactly, and a 0.01mL graduation cannot directly mark 0.125mL. Device capacity and markings are device-specific; ask the dispensing pharmacy to match the sterile device to the labeled concentration and prescribed dose.
Do not self-round, split, dilute, or combine a dose to make it fit a device. Ask the dispensing pharmacy to match the labeled concentration and prescribed volume to a sterile device and to explain the markings before the first use.
Units to Milligrams Conversion Reference
This reference table converts U-100 scale readings to volume and then to milligrams at the three illustrative concentrations. It is arithmetic only; it does not select a dose or establish syringe capacity.
| Syringe Units | Milliliters (mL) | @ 5mg/mL | @ 10mg/mL | @ 20mg/mL |
|---|---|---|---|---|
| 5 units | 0.05 mL | 0.25mg | 0.5mg | 1mg |
| 10 units | 0.1 mL | 0.5mg | 1mg | 2mg |
| 25 units | 0.25 mL | 1.25mg | 2.5mg | 5mg |
| 50 units | 0.5 mL | 2.5mg | 5mg | 10mg |
| 75 units | 0.75 mL | 3.75mg | 7.5mg | 15mg |
| 100 units | 1.0 mL | 5mg | 10mg | 20mg |
Under the stated U-100 arithmetic convention, the 100-unit row is treated as 1mL. At 20mg/mL, 1mL multiplied by 20mg/mL equals 20mg as arithmetic. It is not an instruction to take 20mg and does not override the current branded maximum or a compounded prescription label.
Injection Volume Calculator Reference
For a prescribed dose and the concentration printed on the label, use this arithmetic: Volume (mL) = Desired Dose (mg) ÷ Concentration (mg/mL).
Example 1: 7.5mg with a 5mg/mL vial: Volume = 7.5mg ÷ 5mg/mL = 1.5mL.
Example 2: 10mg with a 10mg/mL vial: Volume = 10mg ÷ 10mg/mL = 1.0mL.
Example 3: 2.5mg with a 20mg/mL vial: Volume = 2.5mg ÷ 20mg/mL = 0.125mL, which is 12.5 U-100 units. The fraction is exact; the measuring device still must be matched by the pharmacy, and you should not self-round or dilute it.
A reference chart can help you discuss the labeled concentration and prescribed dose with your pharmacist. It should not replace the pharmacy label, prescriber instruction, or device-specific demonstration.
Storage and Handling of Compounded Tirzepatide
Storage depends on the actual formulation, container, pharmacy label, and beyond-use date. Keep the vial as the dispensing label directs. If it arrives warm, has a temperature excursion, or its appearance does not match the pharmacy description, pause and ask the dispensing pharmacy before using it.
The FDA currently recommends discarding compounded GLP-1 multidose vials within 28 days after first use, even when a compounder gives a longer opened-use instruction. An earlier pharmacy beyond-use date or expiration still applies. Record the first-use date and ask the dispensing pharmacy to clarify conflicting instructions.
There is no single room-temperature allowance or warming time established here for every compounded formulation. Ask the pharmacy about any temperature excursion or unclear handling instruction before using it.
Injection Technique and Best Practices
Use the sterile syringe, needle, dose, and route specified by the dispensing pharmacy and prescriber. Current FDA guidance recommends a new sterile needle and syringe for each compounded multidose-vial dose and encourages patients to discuss measurement and administration with the provider or compounder. Lilly’s named-product materials require training for the specific presentation; they do not select a universal needle gauge, angle, volume, or device for a compounded formulation.
Supplies Needed: The labeled compounded vial, the pharmacist-matched sterile syringe and needle, and any cleaning supplies, gauze, or sharps container specified or supplied by the dispensing pharmacy. Do not use research-only powder, nonsterile equipment, a reused needle, or a syringe selected solely because its markings resemble this chart.
Injection Sites: The Lilly vial instructions for the named product describe subcutaneous injection into the abdomen, thigh, or back of the upper arm with another person administering there, rotation of injection sites, and avoiding pits, thickened or lumpy skin, tenderness, bruising, scaling, hardness, scars, or other damaged skin. Those are presentation-specific instructions; confirm the site and positioning for your compounded prescription and equipment during training.
Injection Steps:
- Follow the dispensing pharmacy's written instructions for hand hygiene and work area; CDC provider guidance describes aseptic preparation and designated clean medication areas but does not replace your prescription instructions.
- Inspect the vial and label; do not use it if the appearance, concentration, expiration, or beyond-use information does not match your instructions.
- Clean the vial stopper with an alcohol swab as directed; prepare the skin as demonstrated by your clinician.
- Draw only the prescribed volume using the pharmacist-matched sterile device; do not convert from a different concentration.
- Position the skin and syringe as your clinician demonstrated for this prescription and device.
- Insert the needle and inject according to the pharmacy and prescriber instructions.
- Withdraw the needle and follow the pharmacy or prescriber instructions for gauze and pressure; do not improvise handling.
- Dispose of the used needle and syringe only as the dispensing pharmacy's and prescriber's instructions direct; CDC provider guidance describes disposal of used syringes and needles but does not replace your prescription instructions.
- Follow the pharmacy instructions for the vial and discard any material that has exceeded its labeled limit.
Important: Mounjaro and Zepbound labeling describes subcutaneous administration; for a compounded prescription, the pharmacy label and prescriber demonstration control the route and device. If you are unsure whether the dose or route was correct, do not repeat or compensate without contacting your prescriber or pharmacy.
Comparing Compounded Tirzepatide to Brand Mounjaro/Zepbound
The active-ingredient name does not make a compounded product an approved generic or establish therapeutic equivalence. The FDA explains the distinction; compare the actual label, formulation, device, pharmacy instructions, dose, supplies, fees, coverage, and eligibility before discussing cost or switching.
| Factor | Compounded Tirzepatide | Brand Mounjaro/Zepbound |
|---|---|---|
| Tirzepatide Molecule | Tirzepatide as labeled by the pharmacy; other ingredients and formulation may differ | Tirzepatide in the named FDA-approved product |
| Delivery Format | Pharmacy-specified vial or other formulation; confirm the label and device | Current product formats include presentation-specific pens and vials |
| Cost | Varies with pharmacy, dose, supplies, fees, and eligibility | Varies with product, coverage, savings programs, and current pricing |
| FDA Approval | Compounded products are not FDA-approved finished generics; oversight depends on the applicable pharmacy pathway | FDA-approved product labeling applies to the named brand presentation |
| Quality Assurance | State boards primarily oversee 503A pharmacies; FDA also inspects. Registered 503B outsourcing facilities have FDA oversight and current good manufacturing practice requirements | FDA-regulated manufacturing and the named product labeling |
| Potency Consistency | Use the labeled concentration and beyond-use instructions; do not assume guaranteed consistency | Use the labeled strength, expiration, and product instructions |
| Convenience | May require pharmacy-matched manual measurement and formulation-specific handling | Use the presentation-specific pen or vial instructions |
A switch requires a prescriber and pharmacy plan for the new product, concentration, dose, timing, and device. Do not use two tirzepatide products concurrently or treat a brand pen schedule as a compounded-vial instruction.
Related Guides
Frequently Asked Questions
Both current US brand labels start adults at 2.5mg once weekly. Zepbound increases to 5mg after 4 weeks; later increases are in 2.5mg steps after at least 4 weeks at the current dose, based on response and tolerability. Its weight-management maintenance doses are 5, 10, or 15mg weekly; for obstructive sleep apnea they are 10 or 15mg. The current Mounjaro label allows 2.5mg increases after at least 4 weeks if additional glycemic control is needed. Both have an adult maximum of 15mg weekly. These are brand-label references, not approval of a compounded formulation. Follow the exact pharmacy label and prescriber plan for a compounded prescription.
The 5mg/mL, 10mg/mL, and 20mg/mL concentrations shown in this guide are illustrative arithmetic examples, not a universal availability standard. Your dispensing pharmacy label controls the actual concentration, total volume, ingredients, storage instructions, and beyond-use date. Never substitute a concentration from this chart for the concentration on your prescription label.
Use Volume (mL) = prescribed dose (mg) divided by the labeled concentration (mg/mL). The examples in this guide are arithmetic references, not permission to select a dose: 2.5mg is 0.5mL at 5mg/mL, 0.25mL at 10mg/mL, or 0.125mL at 20mg/mL; 15mg is 3mL, 1.5mL, or 0.75mL at those same concentrations. For the arithmetic below, the stated U-100 convention is 100 units per mL; confirm that your labeled device is actually U-100 with the pharmacy. A volume may not fit the capacity or markings of one syringe, so ask the pharmacist to match the sterile measuring device to the labeled concentration and prescribed dose. Do not self-round, split, dilute, or combine measurements to resolve a mismatch.
For the arithmetic below, one stated U-100 unit is treated as 0.01mL; that convention does not guarantee delivery accuracy or establish that a particular device is U-100. At the illustrative concentrations, that volume corresponds to 0.05mg at 5mg/mL, 0.1mg at 10mg/mL, or 0.2mg at 20mg/mL. Values such as 0.125mL (12.5 units), 0.375mL (37.5 units), and 0.625mL (62.5 units) fall between whole-unit markings. Use only the sterile device and measurement instructions matched by your pharmacy or prescriber; do not choose equipment from a generic chart.
Follow the dispensing pharmacy label for storage and beyond-use date. The FDA currently recommends discarding compounded GLP-1 multidose vials within 28 days after first use even when a compounder gives a longer instruction. An earlier pharmacy beyond-use date or expiration still applies. Record the first-use date and ask the pharmacy to clarify conflicting instructions or any temperature excursion or appearance change before using the vial.
Use the sterile syringe and needle specified or supplied by the dispensing pharmacy for the labeled concentration and prescribed volume, plus only the cleaning supplies, gauze, and sharps container specified or supplied by that pharmacy. CDC injection-safety guidance is provider-focused: it describes aseptic technique, new sterile equipment, and designated clean medication-preparation areas; a compounded prescription still requires its own pharmacy instructions. Do not use research-only powder, nonsterile equipment, a reused needle, or a device selected solely because its markings look similar.
In sterile-compounding terminology, CDC notes that USP <797> includes reconstituting among processes used to create a sterile medication. The diluent, volume, preparation method, and usable period depend on the actual product. If your dispensing pharmacy supplies a powder or asks you to perform a preparation step, obtain its exact written sterile-preparation instructions and beyond-use date first. Do not apply a generic bacteriostatic-water recipe or use research-only powder for a prescription injection.
A switch is not automatically seamless. Mounjaro and Zepbound have product-specific approved presentations and labeling, while compounded products are not FDA-approved finished generics or established therapeutic equivalents. A prescriber and dispensing pharmacy should confirm the formulation, labeled concentration, dose, device, timing, and storage plan. Do not combine concurrent tirzepatide products or use the brand schedule to infer a compounded dose.
For current branded tirzepatide labeling, take a missed dose within 96 hours (4 days) when the label permits; if more than 4 days have passed, skip it and take the next dose on the regular day. Keep doses at least 72 hours apart. If you miss multiple doses or use a compounded formulation with different written instructions, contact your prescriber or pharmacy for a restart plan. Do not improvise a restart or accelerated catch-up schedule.